JPH11507541A - 低酸素誘導因子−１および使用方法 - Google Patents

低酸素誘導因子−１および使用方法

Info

Publication number
JPH11507541A
JPH11507541A JP9502264A JP50226497A JPH11507541A JP H11507541 A JPH11507541 A JP H11507541A JP 9502264 A JP9502264 A JP 9502264A JP 50226497 A JP50226497 A JP 50226497A JP H11507541 A JPH11507541 A JP H11507541A
Authority
JP
Japan
Prior art keywords
hif
sequence
dna
nucleotide sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9502264A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507541A5 (enExample
Inventor
エル． セメンザ，グレッグ
Original Assignee
ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン filed Critical ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン
Publication of JPH11507541A publication Critical patent/JPH11507541A/ja
Publication of JPH11507541A5 publication Critical patent/JPH11507541A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
JP9502264A 1995-06-06 1996-06-06 低酸素誘導因子−１および使用方法 Pending JPH11507541A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1
US08/480,473 1995-06-06
PCT/US1996/010251 WO1996039426A1 (en) 1995-06-06 1996-06-06 Hypoxia inducible factor-1 and method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008284139A Division JP2009077729A (ja) 1995-06-06 2008-11-05 低酸素誘導因子−１および使用方法

Publications (2)

Publication Number Publication Date
JPH11507541A true JPH11507541A (ja) 1999-07-06
JPH11507541A5 JPH11507541A5 (enExample) 2004-07-29

Family

ID=23908114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9502264A Pending JPH11507541A (ja) 1995-06-06 1996-06-06 低酸素誘導因子−１および使用方法
JP2008284139A Pending JP2009077729A (ja) 1995-06-06 2008-11-05 低酸素誘導因子−１および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008284139A Pending JP2009077729A (ja) 1995-06-06 2008-11-05 低酸素誘導因子−１および使用方法

Country Status (9)

Country Link
US (3) US5882914A (enExample)
EP (2) EP0833840B1 (enExample)
JP (2) JPH11507541A (enExample)
AT (1) ATE355299T1 (enExample)
AU (1) AU704384B2 (enExample)
CA (1) CA2222279C (enExample)
DE (1) DE69636936T2 (enExample)
IL (1) IL118581A (enExample)
WO (1) WO1996039426A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512847A (ja) * 2003-12-03 2007-05-24 アネシヴァ， インコーポレイテッド Ｈｉｆオリコヌクレオチドデコイ分子
JP2009077729A (ja) * 1995-06-06 2009-04-16 Johns Hopkins Univ School Of Medicine 低酸素誘導因子−１および使用方法
JP2016514950A (ja) * 2013-01-25 2016-05-26 エックスセル・バイオサイエンシズ・インコーポレイテッド 標的細胞の選択的富化のための方法、組成物、キット、及びシステム

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
ATE293633T1 (de) 1997-08-21 2005-05-15 Quark Biotech Inc Hypoxie-regulierte gene
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
AU757930B2 (en) * 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
EP1034267A1 (en) * 1997-12-04 2000-09-13 Genzyme Corporation Compositions and methods for inducing gene expression
CA2322843A1 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford, Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) * 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
AU5810999A (en) * 1998-08-27 2000-03-21 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
AU7748200A (en) * 1999-09-30 2001-04-30 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
US20030180740A1 (en) * 2000-02-22 2003-09-25 Kingsman Alan John Differential expression screening method
CA2418386A1 (en) * 2000-08-07 2002-02-14 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) * 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
CA2447958A1 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
ATE432346T1 (de) * 2001-06-05 2009-06-15 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
ES2649817T3 (es) 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US20050222061A1 (en) * 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
CA2509494A1 (en) * 2002-12-11 2004-06-24 University Of Massachusetts Method of introducing sirna into adipocytes
JP4546454B2 (ja) 2003-01-28 2010-09-15 レクサーン・コーポレイション Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CA2513398C (en) * 2003-01-31 2013-09-10 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
BRPI0515726A8 (pt) * 2004-11-09 2017-09-12 Santaris Pharma As Oligonucleotídeos de lna potentes para a inibição de expressão de hif-1a
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
HUE044182T2 (hu) 2006-06-07 2019-10-28 Genzyme Corp Génterápia amiotrófiás laterális szklerózis és más gerincvelõ-rendellenességek kezelésére
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
EP3146982B1 (en) 2006-10-03 2019-08-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
AU2009213203B2 (en) * 2008-02-14 2013-06-27 Lincoln University Methods and compositions comprising Trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
SI3988660T1 (sl) 2009-05-02 2025-09-30 Genzyme Corporation Genska terapija za nevrodegenerativne motnje
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CN113403338B (zh) 2014-03-28 2025-07-15 华盛顿大学商业中心 乳腺癌和卵巢癌疫苗
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
WO2021247632A1 (en) * 2020-06-02 2021-12-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479948B1 (en) * 1989-06-23 1998-08-26 Genentech, Inc. Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009077729A (ja) * 1995-06-06 2009-04-16 Johns Hopkins Univ School Of Medicine 低酸素誘導因子−１および使用方法
JP2007512847A (ja) * 2003-12-03 2007-05-24 アネシヴァ， インコーポレイテッド Ｈｉｆオリコヌクレオチドデコイ分子
JP2016514950A (ja) * 2013-01-25 2016-05-26 エックスセル・バイオサイエンシズ・インコーポレイテッド 標的細胞の選択的富化のための方法、組成物、キット、及びシステム

Also Published As

Publication number Publication date
EP0833840A4 (en) 2001-12-19
EP1806357A1 (en) 2007-07-11
IL118581A0 (en) 1996-10-16
US6222018B1 (en) 2001-04-24
CA2222279A1 (en) 1996-12-12
AU704384B2 (en) 1999-04-22
EP0833840A1 (en) 1998-04-08
CA2222279C (en) 2011-02-01
EP0833840B1 (en) 2007-02-28
US5882914A (en) 1999-03-16
DE69636936D1 (de) 2007-04-12
ATE355299T1 (de) 2006-03-15
DE69636936T2 (de) 2007-10-31
AU6332696A (en) 1996-12-24
JP2009077729A (ja) 2009-04-16
IL118581A (en) 2000-01-31
WO1996039426A1 (en) 1996-12-12
US6020462A (en) 2000-02-01

Similar Documents

Publication Publication Date Title
EP0833840B1 (en) Hypoxia inducible factor-1 and method of use
WO1996039426A9 (en) Hypoxia inducible factor-1 and method of use
Pevsner et al. n-Sec1: a neural-specific syntaxin-binding protein.
CA2340328C (en) Stable hypoxia inducible factor-1 alpha and method of use
US6395548B1 (en) Methods of modulating of angiogenesis
US6190663B1 (en) Human MAP kinase homolog
JP2010047588A (ja) 新規膜貫通蛋白質をコードする遺伝子
US7501489B2 (en) cDNAs and proteins involved in hypoxia, circadian and orphan signal transduction pathways, and methods of use
JP2005245469A (ja) 腫瘍サプレッサ遺伝子、並びに癌の検出、腫瘍進行のモニタおよび癌処置のための方法
US6077685A (en) Tumor suppressor merlin and antibodies thereof
AU5810999A (en) Sequences characteristic of hypoxia-regulated gene transcription
US6297356B1 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
US6235879B1 (en) Apoptosis modulators that interact with the Huntington's disease gene
US5763174A (en) RNA editing enzyme and methods of use thereof
US20020102552A1 (en) Transcriptional regulation of the human beta3-adrenergic receptor gene
JPWO2000029571A1 (ja) 新規膜貫通蛋白質をコードする遺伝子
JP4324472B2 (ja) アトラスチン
AU723640B2 (en) A human map kinase homolog
US6197932B1 (en) Modulators of actin
US6635751B1 (en) Isolated nucleic acids encoding activated and suppressive forms of ATF6
US7217806B1 (en) Gene defective in APECED and its use
Zhu et al. Expression of a novel isoform of cyclin I in human testis
JP4548938B2 (ja) Ｍｅｋｋ１（セリントレオニンキナーゼ）相互作用性ｆｈａ（フォークヘッド結合ドメイン）タンパク質１（ｍｉｆ１）
US7041497B2 (en) Nuclear factor κB inducing factor
US6995241B1 (en) Splice variant of head trauma induced cytoplasmatic calcium binding protein

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070803

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090402